Susquehanna International Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.7M Sell
30,620
-61,841
-67% -$47.3M ﹤0.01% 2017
2025
Q4
$71.4M Sell
92,461
-97,715
-51% -$66.4M 0.01% 1094
2025
Q3
$107M Buy
190,176
+26,084
+16% +$14.7M 0.01% 856
2025
Q2
$86.1M Buy
164,092
+12,634
+8% +$7.05M 0.01% 837
2025
Q1
$96.1M Buy
151,458
+69,266
+84% +$47.6M 0.02% 668
2024
Q4
$58.5M Buy
82,192
+48,682
+145% +$40.9M 0.01% 1001
2024
Q3
$35.2M Buy
33,510
+3,098
+10% +$3.45M 0.01% 1349
2024
Q2
$32M Sell
30,412
-6,561
-18% -$6.36M 0.01% 1304
2024
Q1
$35.6M Sell
36,973
-53,224
-59% -$50.6M 0.01% 1269
2023
Q4
$79.2M Buy
90,197
+35,337
+64% +$29.1M 0.02% 788
2023
Q3
$45.1M Sell
54,860
-19,157
-26% -$15.1M 0.01% 1076
2023
Q2
$53.2M Sell
74,017
-22,187
-23% -$17.1M 0.01% 951
2023
Q1
$79M Buy
96,204
+15,707
+20% +$11.8M 0.02% 698
2022
Q4
$58.1M Buy
80,497
+57,355
+248% +$42.3M 0.01% 807
2022
Q3
$15.9M Sell
23,142
-25,609
-53% -$16.1M ﹤0.01% 1637
2022
Q2
$28.8M Sell
48,751
-12,561
-20% -$8.16M 0.01% 1177
2022
Q1
$42.8M Sell
61,312
-114,711
-65% -$72.6M 0.01% 1089
2021
Q4
$111M Sell
176,023
-94,140
-35% -$57.9M 0.02% 674
2021
Q3
$163M Sell
270,163
-88,164
-25% -$54.7M 0.02% 602
2021
Q2
$200M Buy
358,327
+144,175
+67% +$73M 0.03% 497
2021
Q1
$101M Sell
214,152
-498,689
-70% -$243M 0.02% 728
2020
Q4
$344M Buy
712,841
+518,331
+266% +$280M 0.06% 257
2020
Q3
$109M Buy
194,510
+90,210
+86% +$54.7M 0.02% 538
2020
Q2
$65M Buy
104,300
+69,067
+196% +$39.2M 0.02% 689
2020
Q1
$17.2M Sell
35,233
-28,736
-45% -$11.9M 0.01% 1286
2019
Q4
$24M Sell
63,969
-198,283
-76% -$66.7M 0.01% 1263
2019
Q3
$72.7M Buy
262,252
+75,791
+41% +$22.4M 0.02% 568
2019
Q2
$58.4M Buy
186,461
+183,150
+5,532% +$61M 0.02% 615
2019
Q1
$1.36M Buy
3,311
+2,459
+289% +$1.01M ﹤0.01% 4413
2018
Q4
$318K Sell
852
-4,505
-84% -$1.65M ﹤0.01% 6888
2018
Q3
$2.16M Sell
5,357
-164,234
-97% -$62.5M ﹤0.01% 3847
2018
Q2
$58.5M Buy
169,591
+137,780
+433% +$43.1M 0.02% 622
2018
Q1
$11M Buy
31,811
+16,564
+109% +$5.76M ﹤0.01% 1699
2017
Q4
$5.73M Buy
15,247
+11,447
+301% +$4.64M ﹤0.01% 2390
2017
Q3
$1.7M Buy
3,800
+3,053
+409% +$1.45M ﹤0.01% 4210
2017
Q2
$367K Sell
747
-1,412
-65% -$618K ﹤0.01% 7217
2017
Q1
$837K Sell
2,159
-59,600
-97% -$22.1M ﹤0.01% 5509
2016
Q4
$22.7M Buy
+61,759
New +$23.5M 0.01% 959
2016
Q3
Sell
-131,534
Closed -$52.8M 8916
2016
Q2
$45.9M Buy
131,534
+94,511
+255% +$36.4M 0.02% 546
2016
Q1
$13.3M Sell
37,023
-3,281
-8% -$1.35M 0.01% 1294
2015
Q4
$21.9M Sell
40,304
-13,489
-25% -$7.31M 0.01% 1069
2015
Q3
$25M Sell
53,793
-86,569
-62% -$46.5M 0.01% 1035
2015
Q2
$71.6M Buy
140,362
+37,819
+37% +$18.5M 0.03% 519
2015
Q1
$46.3M Sell
102,543
-54,628
-35% -$23.2M 0.02% 676
2014
Q4
$64.5M Buy
157,171
+20,850
+15% +$8.2M 0.03% 599
2014
Q3
$49.1M Sell
136,321
-81,804
-38% -$27.4M 0.02% 762
2014
Q2
$61.6M Sell
218,125
-43,850
-17% -$13M 0.03% 590
2014
Q1
$78.7M Buy
261,975
+67,387
+35% +$20.8M 0.04% 435
2013
Q4
$53.6M Buy
194,588
+23,758
+14% +$6.83M 0.02% 619
2013
Q3
$53.4M Buy
170,830
+28,906
+20% +$7.6M 0.03% 570
2013
Q2
$31.9M Buy
+141,924
New +$33M 0.02% 789

Other funds holding REGN

Susquehanna International Group's REGN Position: Q1 2026 in Review

Susquehanna International Group reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, selling an estimated $47.3M and leaving 30,620 shares worth $23.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Susquehanna International Group first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $344M in Q4 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Susquehanna International Group held 30,620 shares of Regeneron Pharmaceuticals worth $23.7M as of Q1 2026.
  • Susquehanna International Group sold 61,841 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $47.3M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2017 holding.
  • Susquehanna International Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Susquehanna International Group's Regeneron Pharmaceuticals position peaked at $344M in Q4 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.